Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Cellules CAR-T autologues ciblant CSPG4 dans les HNSCC en rechute/réfractaire

4 novembre 2026 mis à jour par: UNC Lineberger Comprehensive Cancer Center

Administration de cellules T exprimant des récepteurs d'antigène chimériques spécifiques (CAR) de chondroïtine-sulfate-protéoglycane-4 chez des sujets atteints de carcinome épidermoïde de la tête et du cou (HNSCC)

The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cancer that came back after receiving standard therapy for this cancer. The iC9.CAR-CSPG4 treatment is experimental and has not been approved by the Food and Drug Administration.

How many (dose) of the iC9.CAR. CSPG4 T cells are safe to use in patients without causing too many side effects, and what is the maximum dose that could be tolerated will be investigated. The information collected from the study would help cancer patients in the future.

There are two parts to this study. In part 1, blood will be collected to prepare the iC9.CAR-CSPG4 T cells. Disease fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells. In part 2, the iC9.CAR-CSPG4 T cells are given by infusion after completion of lymphodepletion chemotherapy.

The data from the dose escalation will be used to determine a recommended phase 2 dose (RP2D), which will be decided based on the maximum tolerated dose (MTD). Additionally, recommended phase 2 dose will be tested.

Eligible subjects will receive lymphodepletion chemotherapy standard followed by infusion of iC9-CAR.CSPG4 T cells. After treatment completion or discontinuation, subjects will be followed since involving gene transfer experiments.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

33

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27599
        • Recrutement
        • Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
        • Chercheur principal:
          • Jared Weiss, MD
        • Contact:
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study:

  1. Written informed consent and HIPAA authorization for release of personal health information explained to, understood by and signed by the subject; subject given a copy of the informed consent form.
  2. Age ≥ 18 years at the time of consent.
  3. Karnofsky score of > 60%
  4. Histologically or cytologically confirmed stage recurrent/metastatic squamous cell carcinoma of the head and neck as defined by American Joint Committee on Cancer (AJCC). This includes squamous cancer of: oral cavity, oropharynx, hypopharynx and larynx.

Exclusion Criteria:

  1. Subject with a history or current severe progressive heart disease (congestive heart failure, coronary artery disease, uncontrolled arterial hypertension, uncontrolled arrhythmia, or myocardial infarction in the past 6 months.
  2. Subject with a history of stroke or transient ischemic attack (TIA) within 12 months before procurement.
  3. Subject with a history of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabine.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Chimeric Antigen Receptors

blood will be collected to prepare the iC9.CAR-CSPG4 T cells. Disease-fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells. In part 2, the iC9.CAR-CSPG4 T cells are given by infusion after completion of lymphodepletion chemotherapy.

cyclophosphamide 300 mg/meter square IV

Autres noms:
  • Cytoxane
  • Endoxane
  • Cycloblastine
  • Néosar
  • Revimmuniser
  • Procytox

fludarabine 30 mg/meter square IV × 3 days

Autres noms:
  • Fludara
  • Phosphate de fludarabine

the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Toxicity: NCI-CTCAE
Délai: Up to 4 weeks

Toxicity will be graded as the Number of participants with adverse events (AE)s.

AEs will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Dose Limiting Toxicities (DLTs) is defined as at least possibly related to CAR.B7-H3T cell product administration.

Up to 4 weeks
Toxicity: Cytokine Release Syndrome (CRS)
Délai: Up to 4 weeks

CRS will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus Grading. Grade 1 - Mild: Fever ≥38^ o C, No hypotension, No hypoxia, Grade 2 - Moderate: Fever ≥38^ o C, Hypotension not requiring vasopressors, Hypoxia requiring low-flow nasal cannula (≤6 L/minute) or blow-by, Grade 3 - Severe: Fever ≥ 38^ o C, Hypotension requiring a vasopressor with or without vasopressin, Hypoxia requiring high-flow nasal cannula (>6 L/minute), facemask, nonrebreather mask, or Venturi mask, Grade 4 - Life-threatening: Fever ≥38^oC, Hypotension requiring multiple vasopressors (excluding vasopressin), Hypoxia requiring positive pressure (e.g. Continuous positive airway pressure, BiPAP, intubation, mechanical ventilation), Grade 5 - Death

Up to 4 weeks
Toxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS)
Délai: Up to 4 weeks

Neurotoxicity will be graded according to the Immune effector cell-associated neurotoxicity syndrome (ICANS) criteria.

Immune effector cell-associated neurotoxicity syndrome (ICANS) symptoms will be graded according to the criteria outlined in the protocol on a scale from 1 (mild) to 4 (critical). Cytokine release syndrome (CRS) will be graded according to criteria outlined in the protocol on a scale from 1 (mild) to grade 5 (death).

Up to 4 weeks
Dose Limiting Toxicity
Délai: Up to 4 weeks

An event will be considered a Dose limiting toxicity per NCI CTCAE version 5.0, the CRS Grading and ICANS grading criteria.

  • Grade 3-5 allergic reactions related to the CAR-T cell infusion.
  • A treatment-emergent Grade 3 CRS that does not improve to Grade 0-1 by 72 hours or Grade 4 CRS
  • Grade ≥3 ICANS that is unresponsive to the standard of care interventions and does not decrease to Grade ≤1 within 7 days or grade 4 ICANS of any duration that has evidence of cerebral edema and/or generalized convulsive status epilepticus.
  • Any treatment-emergent Grade 4 non-hematologic AE that does not resolve to Grade 2 within 7 days.
  • Any Grade 5 events are not due to the underlying malignancy.
Up to 4 weeks
Tumor inflammation-associated neurotoxicity (TIAN)
Délai: Up to 4 weeks

TIAN will be assessed as a clinical endpoint using the Tumor Inflammation-Associated Neurotoxicity (TIAN) grading system, a standardized clinician-reported tool for evaluating the severity of neurotoxicity associated with tumor-related inflammatory responses, particularly following immunotherapy. Assessments will be based on neurological examination, mental status, cognitive function, focal neurological deficits, seizure activity, level of consciousness, functional status, and relevant diagnostic investigations (e.g., neuroimaging and cerebrospinal fluid analysis), as clinically indicated. Neurotoxicity will be graded on a four-level scale (Grades 1-4): Grade 1, mild symptoms; Grade 2, moderate symptoms requiring medical intervention or causing functional limitation; Grade 3, severe neurological impairment requiring hospitalization or significantly limiting self-care; and Grade 4, life-threatening neurotoxicity requiring urgent intensive management.

Up to 4 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
The recommended phase 2 dose (RP2D) of iC9-CAR.CSPG4
Délai: Up to 4 weeks

The recommended phase 2 dose (RP2D) for administration of iC9-CAR.CSPG4 T cells will be determined based on the modified 3+3 dose finding rule and the tolerability of iC9-CAR.CSPG4 T cells. tolerability of iC9-CAR.CSPG4 T cells will be assessed by NCI-CTCAE v5, ASTCT Consensus ICANS Grading, and CRS Grading Criteria.

Up to 4 weeks
Objective response rate
Délai: Up to 2 years

The objective response rate will be assessed per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) and immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).

RECIST v1.1: Complete Response (CR) as Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Overall Response Rate (ORR) = CR + PR/total number of subjects.

irRECIST: Complete Response (irCR), Disappearance of all lesions, no new lesions, lymph nodes < 10 mm in short axis; Partial Response (irPR), ≥30% decrease in the sum of target lesions and non-target lesions are irNN; Stable response (irSD), not meeting criteria for irCR, irPR, or irPD; Progressive Disease (irPD), ≥20% increase in tumor burden and minimum 5 mm absolute increase in compared to nadir.

Up to 2 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Progression Free Survival (PFS)
Délai: Up to 2 years

PFS will be measured from the first day of lymphodepletion chemotherapy prior to iC9- CAR.CSPG4 T cell infusion to progression per RECIST 1.1 or death.

Up to 2 years
Overall Survival (OS)
Délai: Up to 2 years

OS will be measured from the first day of lymphodepleting chemotherapy prior to iC9-CAR.CSPG4 T cell infusion to date of death for any cause.

Up to 2 years
Duration of Response (DOR)
Délai: Up to 2 years

DOR is defined as the time from partial response (PR) or better to progressive disease (PD) per RECIST 1.1. and irRECIST.

Up to 2 years
Feasibility of iC9-CAR.CSPG4 T cell therapy
Délai: From cell procurement to 4 weeks after iC9-CAR.CSPG4 T cell infusion.

Feasibility will be determined by measuring the percent of subjects procured that proceed with lymphodepletion followed by iC9-CAR.CSPG4 T cell infusion.

From cell procurement to 4 weeks after iC9-CAR.CSPG4 T cell infusion.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 avril 2024

Achèvement primaire (Estimé)

30 décembre 2028

Achèvement de l'étude (Estimé)

30 novembre 2030

Dates d'inscription aux études

Première soumission

13 octobre 2023

Première soumission répondant aux critères de contrôle qualité

18 octobre 2023

Première publication (Réel)

23 octobre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner